Roka Bioscience revealed that it has completed a Series C round of equity financing, raising $20M. The investor syndicate included participation from all existing investors including OrbiMed Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe Inc. (NASDAQ: GPRO). Established in September 2009 through a spin-off of Gen-Probe’s industrial testing assets and technology, Roka Bioscience is focused on developing rapid, highly accurate molecular assays for food safety testing and other industrial applications.